| Year |
Citation |
Score |
| 2022 |
Zhang YL, Cao JL, Zhang Y, Liao L, Deng L, Yang SY, Hu SY, Ning Y, Zhang FL, Li DQ. RNF144A exerts tumor suppressor function in breast cancer through targeting YY1 for proteasomal degradation to downregulate GMFG expression. Medical Oncology (Northwood, London, England). 39: 48. PMID 35103856 DOI: 10.1007/s12032-021-01631-6 |
0.346 |
|
| 2018 |
Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ. Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. European Journal of Cancer (Oxford, England : 1990). 107: 100-114. PMID 30554073 DOI: 10.1016/j.ejca.2018.11.019 |
0.4 |
|
| 2018 |
Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, et al. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. Clinical Colorectal Cancer. PMID 29636300 DOI: 10.1016/j.clcc.2018.03.006 |
0.365 |
|
| 2012 |
Loupakis F, Zhang W, Gerger A, Yang D, Bohanes PO, Labonte MJ, Benhaim L, Wakatsuki T, Ning Y, Wilson PM, El-Khoueiry R, El-Khoueiry AB, Iqbal S, Barzi A, Giamas G, et al. LMTK3 polymorphism in patients with metastatic colon cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 471. PMID 27983134 DOI: 10.1200/jco.2012.30.4_suppl.471 |
0.321 |
|
| 2012 |
Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models. Molecular Cancer Therapeutics. 11: 1353-64. PMID 22391039 DOI: 10.1158/1535-7163.Mct-11-0915 |
0.356 |
|
| 2010 |
Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, Wilson PM, Pohl A, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5591-602. PMID 20935157 DOI: 10.1158/1078-0432.CCR-10-2092 |
0.346 |
|
| 2010 |
Zeineldin R, Ning Y, Hudson LG. The constitutive activity of epidermal growth factor receptor vIII leads to activation and differential trafficking of wild-type epidermal growth factor receptor and erbB2. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 58: 529-41. PMID 20159766 DOI: 10.1369/Jhc.2010.955104 |
0.593 |
|
| 2008 |
Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley BP, Stack MS, Hudson LG. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Research. 68: 4606-13. PMID 18559505 DOI: 10.1158/0008-5472.Can-07-5046 |
0.599 |
|
| 2007 |
Ning Y, Buranda T, Hudson LG. Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae/raft-dependent endocytic pathway. The Journal of Biological Chemistry. 282: 6380-7. PMID 17179151 DOI: 10.1074/Jbc.M610915200 |
0.679 |
|
| 2005 |
Ning Y, Zeineldin R, Liu Y, Rosenberg M, Stack MS, Hudson LG. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Research. 65: 9280-6. PMID 16230389 DOI: 10.1158/0008-5472.Can-05-0407 |
0.603 |
|
| 1998 |
Mari BP, Anderson IC, Mari SE, Ning Y, Lutz Y, Kobzik L, Shipp MA. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism Journal of Biological Chemistry. 273: 618-626. PMID 9417124 DOI: 10.1074/jbc.273.1.618 |
0.311 |
|
| Show low-probability matches. |